RxDoctor Payments Data

Jill Fuhrmann

Family · Gainesville, TXNPI 1952535098

Payments from drug & device makers

$1,159in general payments, 2019–2025

Across 61 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$218
  • Astellas Pharma US Inc$177
  • Novo Nordisk$170
  • AstraZeneca$112
  • Phathom Pharmaceuticals, Inc.$58
  • Lilly USA, LLC$44
  • plus $380 from 15 others

What the payments were for

  • Food & beverage$1,159100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,159 in reported general payments places this provider in the 70th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$98,779
Medicare patients
201
Services billed
1,491

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide45$66,497
RybelsusSemaglutide29$38,160
EliquisApixaban60$27,533
XareltoRivaroxaban33$20,946
FarxigaDapagliflozin Propanediol16$14,825
JanuviaSitagliptin Phosphate15$12,775
JardianceEmpagliflozin13$12,669
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog22$9,741
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$9,712
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,281
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$6,516
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$3,829
Gabapentin254$3,532
Atorvastatin Calcium252$2,642
Memantine Hcl65$2,570

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$170$104,65774 claims
PfizerEliquis$36$27,53360 claims
AstraZenecaFarxiga, Breztri Aerosphere$112$22,10528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 15,456 family providers in Texas.

Other family in Gainesville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →